Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discusses biomarker findings and mature clinical results from KEYNOTE-052, which explored first-line pembrolizumab (Keytruda) in cisplatin-ineligible advanced urothelial carcinoma.